Network analysis of drug-related problems in hospitalized patients with hematologic malignancies
Myeong Gyu Kim(Seoul National University), Jung Mi Oh(Seoul National University), Eunhee Ji(Gachon University), In‐Wha Kim(Seoul National University), Jae Hyun Kim(Seoul National University), Yun-Kyoung Song(Seoul National University), Sung‐Soo Yoon(Seoul National University Hospital), Youngil Koh(Seoul National University), Yoon-Sook Cho(Seoul National University Hospital), Hyun Jee Kim, Chae Reen Jeong(Seoul National University), Kyung Im Kim(Korea University)
Cited by 10
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
|The Lancet|2023|194
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
|Blood|2014|140